INFECTION OF THE HUMAN MONOCYTIC CELL-LINE MONO MAC6 WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 AND TYPE-2 RESULTS IN LONG-TERM PRODUCTION OF VIRUS VARIANTS WITH INCREASED CYTOPATHOGENICITY FOR CD4+ T-CELLS by LAGESTEHR, J et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INFECTION OF THE HUMAN MONOCYTIC CELL-LINE MONO
MAC6 WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 AND
TYPE-2 RESULTS IN LONG-TERM PRODUCTION OF VIRUS
VARIANTS WITH INCREASED CYTOPATHOGENICITY FOR CD4+
T-CELLS
Citation for published version:
LAGESTEHR, J, NIEDRIG, M, GELDERBLOM, HR, SIMBRANDENBURG, JW, URBANSCHRIEFER, M,
RIEBER, EP, HAAS, JG, RIETHMULLER, G & ZIEGLERHEITBROCK, HWL 1990, 'INFECTION OF THE
HUMAN MONOCYTIC CELL-LINE MONO MAC6 WITH HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
AND TYPE-2 RESULTS IN LONG-TERM PRODUCTION OF VIRUS VARIANTS WITH INCREASED
CYTOPATHOGENICITY FOR CD4+ T-CELLS' Journal of Virology, vol 64, no. 8, pp. 3982-3987.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Virology
Publisher Rights Statement:
 Copyright © 2013 by the American Society for Microbiology.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
JOURNAL OF VIROLOGY, Aug. 1990, p. 3982-3987
0022-538X/90/083982-06$02.00/0
Copyright © 1990, American Society for Microbiology
Infection of the Human Monocytic Cell Line Mono Mac6 with
Human Immunodeficiency Virus Types 1 and 2 Results
in Long-Term Production of Virus Variants with
Increased Cytopathogenicity for CD4+ T Cells
J. L'AGE-STEHR,l* M. NIEDRIG,1 H. R. GELDERBLOM,l J. W. SIM-BRANDENBURG,'
M. URBAN-SCHRIEFER,1 E. P. RIEBER,2 J. G. HAAS,2 G. RIETHMULLER,2
AND H. W. L. ZIEGLER-HEITBROCK2
Department of Virology, Robert Koch-Institut des Bundesgesundheitsamtes, D 1000 Berlin-65,1
Institut fur Immunologie der Universitat Munchen, Munich,2 Federal Republic of Germany
Received 5 December 1989/Accepted 3 May 1990
The recently established human monocytic cell line Mono Mac6 expressing distinct characteristics of mature
monocytes/macrophages was tested for its susceptibility to infection with human immunodeficiency virus.
Inoculation of the cells with the T-cell-tropic human immunodeficiency virus strains human T-lymphotropic
virus type IIIB and lymphadenopathy-associated virus type 2 led to a noncytopathic productive infection
becoming apparent only after a latency period of up to 56 days. The infectibility of the Mono Mac6 cells was
dependent on low levels of CD4 expression, as demonstrated by blocking experiments with various CD4-specific
antibodies. Increasing with time after infection (>200 days), the cultured Mono Mac6 cells released virus
variants which showed shortened latency periods when passaged onto uninfected Mono Mac6 cells. Also,
cytopathogenicity for several CD4+ T cells of the Mono Mac6-derived virus was drastically increased; thus, the
infection of the H9 cell line with low doses of virus (<0.1 50% tissue culture infective dose per cell) led to giant
syncytium formation within 1 day and subsequent death of all fused cells. We propose Mono Mac6 cells as a
new model for the study of human immunodeficiency virus infecting the monocyte/macrophage lineage,
particularly with regard to virus-host cell interaction and the influence of cell differentiation and activation on
latency and development of virulence. The human immunodeficiency virus-infected Mono Mac6 cell may also
serve as a valuable tool for in vitro testing of antiviral therapies.
The human immunodeficiency virus (HIV) infects human
T cells as well as non-T cells of the monocyte/macrophage
lineage, B cells, follicular dendritic cells, and microglia, and
there is evidence that bone marrow stem cells and even
fibroblasts may be infected with HIV (17).
In vitro HIV infection of T cells expressing surface CD4
molecules causes cell fusion and syncytium formation and
results in death of the fused cells (18). In monocytes and
macrophages which express only a few CD4 molecules on
their surfaces, HIV infection induces no detectable cyto-
pathic effects (9). HIV can persist for prolonged periods in
monocytes and macrophages (12, 19). It has been suggested
that these cells may thus serve as a major HIV reservoir in
vivo. Furthermore, when circulating in the blood, they may
play an important role in dissemination of the HIV infection
throughout the organism, particularly to the central nervous
system (13, 16, 24, 26).
To study mechanisms of HIV infection in monocytes/
macrophages and to investigate their role in the maintenance
of virus latency, as well as the influence of host cell
differentiation on HIV pathogenesis, thus far only primary
cultures of monocytes/macrophages or dendritic cells from
peripheral blood or cell lines representing the early mono-
blastic stages of differentiation such as U937 (32) or THP-1
(34) have been used (1, 3, 7, 13, 16, 24).
Thus, the recently established mature human monocytic
cell line Mono Mac6, derived from a patient with monoblas-
tic leukemia, may constitute an informative cell model for
* Corresponding author.
the study of HIV-host cell interaction. This line shows
characteristics of mature blood monocytes (phagocytosis,
Fc receptor, and CD14 marker) and expresses minimal
amounts of CD4 at the cell surface (36).
Mono Mac6 cells growing in suspension culture were
maintained in RPMI 1640 medium supplemented with 20%
fetal calf serum, nonessential amino acids, 1 ,uM oxalace-
tate, and 1 ,uM pyruvate (complete medium) at 37°C in 5%
CO2 as described before (36). Every 3 to 4 days cells were
split 1:3 and fresh medium was added. The human T-
lymphoblastoid cell lines H9 and K37 and the HIV type 1
(HIV-1) strain human T-lymphotropic virus type IIIB
(HTLV-IIIB) (8) were originally obtained through the cour-
tesy of R. C. Gallo and M. Popovic, National Institutes of
Health, Bethesda, Md., and HIV-2 strain lymphadenopathy-
associated virus type 2 (LAV-2) (4) propagated in CEM cells
was kindly provided by L. Montagnier, Institute Pasteur,
Paris, France, and was passaged in H9 cells. Cell lines H9,
Molt4, and MT4 (15) were maintained in RPMI 1640 medium
with 10% fetal calf serum at 37°C in 5% CO2. All cell lines,
when contaminated with mycoplasma during handling, were
treated with fresh human serum, and absence of myco-
plasma infection in each HIV-infected and control culture
was controlled every 2 weeks by using Vero cells as an
indicator culture system (35) and occasionally electron mi-
croscopy of HIV-infected Mono Mac6 cells.
Tissue culture supernatants of recently infected HTLV-
ITIB- and LAV-2-infected H9 cells were harvested 7 to 8
days after infection, clarified by centrifugation (750 x g for
10 min), and stored as virus stock at -70°C. The tissue
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FIG. 1. Kinetics of onset and long-term production of HIV
antigen p24 by HTLV-IIIB (A)- and LAV-2 (0)-infected Mono
Mac6 cells.
culture infectious dose 50% endpoint (TCID50) was deter-
mined in microdilution plates by inoculating quadruplicate
wells containing 5 x 104 HTLV-I genome-containing MT-4
cells (15) per well with undiluted and serial 10-fold dilutions
of cell-free supernatants. MT-4 cell cultures were monitored
daily microscopically for HIV-induced cell fusion and syn-
cytium formation. The TCID50 was defined as the last
dilution which induced syncytium formation at day 6. Viral
p24 antigen was determined in cell-free supernatants by the
Du Pont HIV p24-enzyme-linked immunosorbent assay sys-
tem (New England Nuclear, Dreieich, Federal Republic of
Germany) detecting antigens of HIV-1 as well as HIV-2.
To establish HIV-1 and HIV-2 infections in Mono Mac6
cells, 2 x 105 cells in 1 ml of complete RPMI 1640 medium
were incubated at 37°C for 30 min with a 1-ml supernatant of
HTLV-IIIB- or LAV-2-infected H9 cells (0.1 to 1.0 TCID50
per Mono Mac6 cell). Unbound virus was removed by
washing and centrifugation of the cells at 400 x g three
times. The cell pellet was suspended in 2 ml of complete
medium and plated into a well of 24-well plastic plates for
further incubation at 37°C in 5% CO2. Every 3 to 4 days 1 ml
of the suspended cell suspension was removed and fresh
medium was added. Harvested samples of cell-free superna-
tants were titrated for p24 antigen content and TCID50 as
described above.
Depending on the initial infectious dose, virus release into
the culture supernatant was detected 7 to 21 days after
infection with LAV-2, but not before days 21 to 56 after
infection with HTLV-IIIB. After its first detection, virus
production increased steadily over a period of 10 to 20 days,
reaching levels of 30 to 100 ng of p24 per ml (Fig. 1) and
infectious titers of 2 x 103 to 1 x 104 TCID50 per ml of
supernatant when assessed on MT-4 cells. After this phase,
rather constant levels of p24 viral antigen (>30 ng/ml) and
infectious titers (>5 x 103/ml) were observed for more than
300 days. Thus, the amount of infectious virus produced is
about one-tenth of that released by infected H9 cells (see
Table 2).
Infected, virus-producing Mono Mac6 cells did not exhibit
major changes in growth behavior or morphology except for
the occasional occurrence of up to 10% discretely enlarged
cells. Less than 0.1% of the cells could be identified as
multinucleated cells.
Thin-section electron microscopy (10) of Mono Mac6 cells
220 days after HIV inoculation revealed morphologically
mature HIV particles either released from the Mono Mac6
cells or predominantly contained within cytoplasmic vacu-
oles (Fig. 2). These vacuoles were morphologically compa-
rable to those described (12, 13) for HIV-infected peripheral
blood monocytes/macrophages. Occasionally, budding from
the plasma membrane to the extracellular space or into
vacuoles was observed. Viral buds were densely studded
with envelope knobs (Fig. 2a), while morphologically mature
particles showed varying degrees of loss of envelope projec-
tions (11).
Cytoplasmic viral antigen was detected in <10 to a max-
imal 30% of the chronically infected Mono Mac6 cells (Fig.
3) by alkaline phosphatase-anti-alkaline phosphatase
(APAAP) immunocytochemistry (5) with monoclonal anti-
bodies specific for the p24 antigen of HIV-1 and HIV-2 (22,
23).
In view of the described low levels of CD4 expression in
Mono Mac6 cells (36), it was of interest to know whether
primary HIV infection is still dependent on the presence of
this receptor. Using the APAAP technique, we found that 2
to 8% of the uninfected Mono Mac6 cells exhibited weak
staining with monoclonal anti-CD4 antibodies MT151 and
MT310 (27), which is consistent with earlier flow cytometry
studies (36). The low expression of CD4 was further con-
firmed by Northern (RNA) blot analysis of total and poly(A)-
enriched RNAs exhibiting no hybridization signal with a
CD4-specific probe (data not shown).
To block the CD4 receptor, we preincubated Mono Mac6
cells (2 x 105/ml) for 60 min at 37°C in complete medium
containing 20 ,ug of purified anti-CD4 monoclonal antibodies
(MT151, MT310, and MT406). MT151 and MT310 had been
found previously to block HIV-1 or HIV-2 infection of H9
cells (30), while MT406, which recognizes a CD4 epitope not
involved in viral gpl20 binding (Rieber et al., unpublished
data), had no effect. After preincubation, the treated Mono
Mac6 cells were infected with 1.0 TCID50 of HTLV-IIIB or
LAV-2 passaged in H9 cells per cell and further incubated at
37°C for 30 min in the presence of monoclonal antibodies.
After washing and sedimentation, cells were suspended in
complete medium containing 10 ,ug of the appropriate mono-
clonal antibodies per ml. Furthermore, the cells were main-
tained in medium containing 10 ,ug of monoclonal antibodies
per ml for up to 60 days.
In four independent experiments utilizing MT151 and
MT310, no HIV replication was observed for up to 160 days
after infection (Table 1), while HIV infection and replication
were not affected in the presence of mouse immunoglobulin
G isotype controls or in the presence of 20 ,ug of MT406 per
ml. These results indicate that HIV infection of Mono Mac6
cells depends on low levels of CD4.
In contrast, preliminary experiments with subneutralizing
doses of an anti-HIV-2 serum from an asymptomatic HIV-
2-infected patient indicate that, in the presence of blocking
concentrations of anti-CD4 monoclonal antibodies, infection
of Mono Mac6 cells with antibody-coated HIV-2 may also
occur via Fc receptors (data not shown).
HIV-1 and HIV-2 strains produced by long-term infected
Mono Mac6 cells exhibited at least two striking differences
in biological properties when compared with the original
strains grown in H9 cells. First, when cell-free supernatant
harvested later than 150 days after infection of HTLV-IIIB-
or LAV-2-infected Mono Mac6 cells (containing 5 x 103 to 1
x 104 TCID50 and 40 to 90 ng of p24 antigen per ml) was used
to infect Mono Mac6 cells, a significantly shortened latency
period of 4 to 6 days versus 21 to 56 days for primary
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FIG. 2. Thin-section electron microscopy of Mono Mac6 cells 230 days after infection with LAV-2. (a) Large cytoplasmic vacuoles are
filled with numerous mature HIV particles. (b) Occasionally, virus formation can be observed at the cell surface. The budding HIV-2 is
densely studded with envelope projections, while the p55 gag protein precursor material is closely attached to the prospective viral envelope.
(c) Morphologically mature HIV-2 particles characterized by their cone-shaped cores show a relatively high number of envelope projections.
Bars, 100 nm.
infection with H9 cell-derived virus was observed. Second,
in six independent inoculation infection experiments, it was
found that the HIV-1 and HIV-2 strains released later than
about 150 days after infection from long-term cultured,
infected Mono Mac6 cells displayed a distinctly increased
cytopathogenicity for CD4+ T-cell lines such as H9 or Molt4
and that these cells died within a few days.
To assess changes in cytopathogenicity for H9 cells in
more detail, supernatants were harvested from Mono Mac6
cells later than 200 days after infection. Cell-free superna-
tants were titrated for p24 antigen content and TCID50 on
MT-4 cells as described above, and 0.1 ml of undiluted or
serially 10-fold-diluted supernatant was added to replicate
microdilution wells containing 2 x 104 H9 cells per well. For
J. VIROL.
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FIG. 3. Immunocytochemistry of LAV-2-infected Mono Mac6
cells (36) at day 180 after infection: APAAP technique (5), using
anti-p24 monoclonal antibody 6-D-12 (23).
comparison, cell-free supernatants from H9 cells infected
with HTLV-IIIB and LAV-2 were used. Cultures were
monitored daily for syncytium formation. Syncytium forma-
tion occurred as soon as 6 to 24 h after infection in H9 cell
cultures exposed to 0.001 to 0.1 TCID50 of Mono Mac6
cell-derived virus strains per cell (Table 2), whereas 0.01 to
1.0 TCID50 of the H9 derived virus strains per cell induced
syncytium formation only 3 to 4 days later. The Mono Mac6
cell-derived virus variants induced giant confluent syncytia
which involved several hundred cells each and virtually all
H9 cells in the cultures. Syncytium formation resulted 2 to 3
days later in dead giant cells containing condensed nuclei.
Cell viability as assessed visually and by trypan blue exclu-
sion at day 6 after infection was <1% in H9 cells infected
with the Mono Mac6 cell-derived virus, while >80% of the
H9 cells infected with up to 1,000-fold-higher infectious
doses of H9 cell-derived virus were viable at that time (Table
2). Another sign for the increased and early cytocidal effect
of Mono Mac6 cell-derived HIV strains was the absence of
p24 antigen production of such infected H9 cells compared
with a steady increase of p24 antigen content in supernatants
of H9 cells infected with HTLV-IIIB or LAV-2 derived from
TABLE 1. Inhibition of HIV infection in Mono Mac6
cells by CD4-specific antibodies
Virus replication in Mono Mac6 cells >80 days
Infection in after primary infection with:
presence of HTLV-IIIB LAV-2
CD4-specific
antibodiesa p24 content p24 content TCIDsWml
(ng/ml) TCID50WMl (ng/ml) TCD0M
MT151 <0.0 ob <0.1 0
MT310 <0.1 0 <0.1 0
MT406 >50 >104 >50 >104
None >50 >104 >50 >104
Isotype control >50 >104 >50 >104
a Designation of mouse monoclonal CD4-specific and immunoglobulin G
isotype control antibodies.
b 0, No infectious virus (TCID50) detectable in a 1-ml supernatant of Mono
Mac6 cells.
TABLE 2. Demonstration of increased virulence for H9 cells of
HIV-1 and HIV-2 strains released from Mono Mac6 cells
>200 days after infection with HTLV-IIIB or LAV-2
Infectious dosea Start of % Via-
Virus Grown in syncytium bility
strain cell line ng of p24 TCID50 formation on day
per ml cell (days) +6
HTLV-IIIB H9 520.0 1.0 3 80-95
52.0 0.1 3 80-95
5.2 0.01 >4 80-95
Mono Mac6 36.0 0.1 <1 <1
3.6 0.01 1 <1
0.4 0.001 2 <1
LAV-2 H9 660.0 0.1 3 80-95
66.0 0.01 3 80-95
6.6 0.001 4 80-95
Mono Mac6 89.0 0.1 <1 <1
8.9 0.01 1 <1
0.9 0.001 2 <1
a Content of p24 antigen and TCID50 were determined per milliliter of
cell-free culture supernatant harvested 7 days after infection of H9 cells and
later than 200 days after infection of Mono Mac6 cells and used for infection
of H9 cells.
H9 cells. Thus, the phenotype as well as the kinetics of the
cytopathic effect were drastically altered when the Mono
Mac6 cell-passaged virus was used.
Whether the reproducible appearance of cytocidal HIV-1
and HIV-2 strains in long-term cultured Mono Mac6 cells
reflects a mutation or selection of the virus during multipli-
cation in the CD4-deficient monocytic cell line or whether it
reflects another mechanism involving host cell differentia-
tion factors remains to be analyzed on the molecular genetic
level.
It has been reported previously (3, 6, 7, 14, 25) that a
productive HIV infection in monoblastoid cell line U937 is
influenced by the state of cellular differentiation. According
to these observations, virus production ceased 2 to 3 days
after infection and was reinduced after differentiation induc-
tion. Also, in other lentivirus infections, such as caprine
arthritis encephalitis virus, virus production appears to be
determined by the stage of differentiation of the monocytic
cells harboring the virus (20). The increased cytopathogenic-
ity of HIV for CD4+ T-cell lines becomes apparent only
after the initial latency period: whether this reflects the
generation of more cytopathic HIV strains isolated from
individual patients during late stages of their disease remains
to be investigated (2, 28, 33).
The question of whether the generation of more cytocidal
HIV variants is enhanced by a particular monocytic cellular
environment in defined stages of cellular differentiation can
now be addressed.
To our knowledge, this is the first report on the reproduc-
ible development of HIHV variants with increased cytopatho-
genicity for H9 cells of H9-derived HTLV-IIIB and LAV-2
strains by long-term culturing in a low-CD4-expressing
monocytic cell line.
From the experiments described, the Mono Mac6 cells
appear to represent an informative model for virological and
molecular studies on HIV pathogenetic mechanisms. Fur-
thermore, they should be a valuable tool for preclinical
testing of antiviral drugs which may act differently in HIV-
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infected T cells compared with chronically infected mono-
cytes/macrophages.
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